{"nctId":"NCT02686658","briefTitle":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","startDateStruct":{"date":"2015-12-15","type":"ACTUAL"},"conditions":["Geographic Atrophy","Dry Age-Related Macular Degeneration"],"count":286,"armGroups":[{"label":"Avacincaptad Pegol 1 mg [Part 1]","type":"EXPERIMENTAL","interventionNames":["Drug: Avacincaptad Pegol"]},{"label":"Avacincaptad Pegol 2 mg [Part 1]","type":"EXPERIMENTAL","interventionNames":["Drug: Avacincaptad Pegol"]},{"label":"Sham [Part 1]","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham"]},{"label":"Avacincaptad Pegol 2 mg (Avacincaptad Pegol 2mg+Sham) [Part 2]","type":"EXPERIMENTAL","interventionNames":["Drug: Avacincaptad Pegol","Other: Sham"]},{"label":"Avacincaptad Pegol 4 mg (Avacincaptad Pegol 2mg+Avacincaptad Pegol 2mg) [Part 2]","type":"EXPERIMENTAL","interventionNames":["Drug: Avacincaptad Pegol"]},{"label":"Sham (Sham+Sham) [Part 2]","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham"]}],"interventions":[{"name":"Avacincaptad Pegol","otherNames":["Zimura (previous name)","IZERVAY","ARC1905"]},{"name":"Sham","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants of either gender aged â‰¥ 50 years\n* Diagnosis of Non-foveal GA secondary to dry AMD\n\nExclusion Criteria:\n\n* Evidence of Choroidal Neovascularization (CNV)\n* GA secondary to any condition other than AMD\n* Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals\n* Any intraocular surgery or thermal laser within three (3) months of trial entry\n* Any prior thermal laser in the macular region, regardless of indication\n* Any ocular or periocular infection in the twelve (12) weeks\n* Previous therapeutic radiation in the region of the study eye\n* Any sign of diabetic retinopathy in either eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence","description":"The least squares mean change in geographic atrophy (GA) from baseline to Month 12 was measured by fundus autofluorescence (FAF). The square root of the GA area was used in the analysis. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for this primary endpoint; the Zimura 1 mg group was for descriptive purposes only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.292","spread":"0.077"},{"groupId":"OG001","value":"0.402","spread":"0.075"},{"groupId":"OG002","value":"0.321","spread":"0.074"},{"groupId":"OG003","value":"0.444","spread":"0.072"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters","description":"The least squares mean change in best-corrected visual acuity (BCVA) from baseline to Month 12 was measured using early treatment diabetic retinopathy study \\[ETDRS\\] letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.90","spread":"2.66"},{"groupId":"OG001","value":"-9.29","spread":"2.59"},{"groupId":"OG002","value":"-3.79","spread":"3.11"},{"groupId":"OG003","value":"-3.51","spread":"2.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters","description":"The least squares mean change in low luminance (LL) BCVA from baseline to Month 12 was measured using ETDRS letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":"3.40"},{"groupId":"OG001","value":"-1.41","spread":"3.30"},{"groupId":"OG002","value":"1.53","spread":"3.53"},{"groupId":"OG003","value":"2.97","spread":"3.39"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":26},"commonTop":["Conjunctival haemorrhage *","Urinary tract infection","Neovascular age-related macular degeneration*","Intraocular pressure increased","Fall"]}}}